blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3050563

EP3050563 - ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.03.2019
Database last updated on 13.09.2024
FormerThe patent has been granted
Status updated on  06.04.2018
FormerGrant of patent is intended
Status updated on  21.12.2017
FormerRequest for examination was made
Status updated on  14.03.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612 / US
[2016/31]
Inventor(s)01 / Dibas, Mohammed I.
1658 Honors Circle
Corona, CA 92883 / US
02 / Chow, Ken
20 Tidal Surf
Newport Coast, California 92657 / US
03 / Donello, John E.
34041 Pequito Drive
Dana Point, California 92629 / US
04 / Garst, Michael E.
2627 Raqueta Drive
Newport Beach, California 92660 / US
05 / Gil, Daniel W.
2541 Point Del Mar
Corona Del Mar, California 92625 / US
06 / Wang, Liming
16 Trinity
Irvine, California 92612 / US
 [2018/19]
Former [2016/36]01 / Dibas, Mohammed I.
1658 Honors Circle
Corona, CA92883 / US
02 / Chow, Ken
20 Tidal Surf
Newport Coast, California 92657 / US
03 / Donello, John E.
34041 Pequito Drive
Dana Point, California 92629 / US
04 / Garst, Michael E.
2627 Raqueta Drive
Newport Beach, California 92660 / US
05 / Gil, Daniel W.
2541 Point Del Mar
Corona Del Mar, California 92625 / US
06 / Wang, Liming
16 Trinity
Irvine, California 92612 / US
Former [2016/31]01 / Dibas, Mohammed I.
28871 Niguel Vista
Laguna Niguel, California 92677 / US
02 / Chow, Ken
20 Tidal Surf
Newport Coast, California 92657 / US
03 / Donello, John E.
34041 Pequito Drive
Dana Point, California 92629 / US
04 / Garst, Michael E.
2627 Raqueta Drive
Newport Beach, California 92660 / US
05 / Gil, Daniel W.
2541 Point Del Mar
Corona Del Mar, California 92625 / US
06 / Wang, Liming
16 Trinity
Irvine, California 92612 / US
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2016/31]
Application number, filing date16161920.016.09.2011
[2016/31]
Priority number, dateUS20100383370P16.09.2010         Original published format: US 383370 P
[2016/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3050563
Date:03.08.2016
Language:EN
[2016/31]
Type: B1 Patent specification 
No.:EP3050563
Date:09.05.2018
Language:EN
[2018/19]
Search report(s)(Supplementary) European search report - dispatched on:EP13.05.2016
ClassificationIPC:A61K31/4174, A61P27/06
[2016/31]
CPC:
A61K31/4174 (EP,CN,KR,RU,US); C07D233/64 (EP,KR,RU,US); A61K31/4164 (CN,KR,US);
A61K9/0014 (KR,US); A61P27/02 (EP); A61P27/06 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/31]
TitleGerman:ESTER-PRODRUGS AUS [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL ZUR BEHANDLUNG VON HAUTERKRANKUNGEN UND -STÖRUNGEN[2016/31]
English:ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS[2016/31]
French:PROMÉDICAMENTS D'ESTER DE [3- (1- (1H-IMIDAZOL-4-YL) ÉTHYL) -2-MÉTHYLPHÉNYL] MÉTHANOL POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS DE LA PEAU[2016/31]
Examination procedure23.03.2016Examination requested  [2016/31]
15.03.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
15.05.2017Amendment by applicant (claims and/or description)
22.12.2017Communication of intention to grant the patent
28.03.2018Fee for grant paid
28.03.2018Fee for publishing/printing paid
28.03.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11760961.0  / EP2616067
Opposition(s)12.02.2019No opposition filed within time limit [2019/16]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
15.05.2017Request for further processing filed
15.05.2017Full payment received (date of receipt of payment)
Request granted
31.05.2017Decision despatched
Fees paidRenewal fee
23.03.2016Renewal fee patent year 03
23.03.2016Renewal fee patent year 04
23.03.2016Renewal fee patent year 05
27.09.2016Renewal fee patent year 06
27.09.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL09.05.2018
CY09.05.2018
FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
MK09.05.2018
RS09.05.2018
SM09.05.2018
IS09.09.2018
LU16.09.2018
MT16.09.2018
[2020/32]
Former [2020/31]AL09.05.2018
CY09.05.2018
FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
MK09.05.2018
RS09.05.2018
SM09.05.2018
LU16.09.2018
MT16.09.2018
Former [2020/08]AL09.05.2018
FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RS09.05.2018
SM09.05.2018
LU16.09.2018
MT16.09.2018
Former [2019/51]AL09.05.2018
FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RS09.05.2018
SM09.05.2018
LU16.09.2018
Former [2019/30]FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RS09.05.2018
SM09.05.2018
LU16.09.2018
Former [2019/24]FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
MC09.05.2018
RS09.05.2018
SM09.05.2018
Former [2019/12]FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
RS09.05.2018
SM09.05.2018
Former [2018/51]FI09.05.2018
HR09.05.2018
LT09.05.2018
LV09.05.2018
RS09.05.2018
Former [2018/47]FI09.05.2018
LT09.05.2018
Documents cited:Search[A]WO9514007  (SCHERING CORP [US], et al) [A] 1-11* claim 1 *;
 [A]WO2005034998  (ALLERGAN INC [US], et al) [A] 1-11 * pages 9,18 *;
 [A]WO2006036480  (ALLERGAN INC [US], et al) [A] 1-11 * pages 7-10; claim 1 *;
 [A]WO2009089132  (ALLERGAN INC [US], et al) [A] 1-11 * pages 14-19 * * claim - *;
 [A]WO2010091209  (ALLERGAN INC [US], et al) [A] 1-11 * page 7 *;
 [A]WO2010093930  (ALLERGAN INC [US], et al) [A] 1-11 * claim - * * page 15 * * page 20; table 2 *;
 [A]  - GENTILI FRANCESCO ET AL, "Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NETHERLANDS, (20070101), vol. 7, no. 2, ISSN 1568-0266, pages 163 - 186, XP009153333 [A] 1-11 * pages 166-168 *
 [A]  - LEE V H L ET AL, "Prodrugs for improved ocular drug delivery", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 3, no. 1, doi:10.1016/0169-409X(89)90003-3, ISSN 0169-409X, (19890101), pages 1 - 38, (19890101), XP023861046 [A] 1-11 * page 8 *

DOI:   http://dx.doi.org/10.1016/0169-409X(89)90003-3
 [A]  - TESTA B ET AL, "DESIGN OF INTRAMOLECULARLY ACTIVATED PRODRUGS", DRUG METABOLISM REVIEWS, MARCEL DEKKER, NEW YORK, NY, US, (19980101), vol. 30, no. 4, ISSN 0360-2532, pages 787 - 807, XP009009563 [A] 1-11 * the whole document *
by applicantUS7491383
 WO2010093930
    - HUI, Y.-H, JOUMAL OF CHROMATOGRAPHY, (1997), vol. 762, no. 1 + 2, pages 281 - 291
    - STOILOV, "Synthesis of detomidine and medetomidine metabolites: 1,2,3-trisubstituted arenes with 4'(5')- imidazolylmethyl groups", JOUMAL OF HETEROCYCLIC CHEMISTRY, (1993), vol. 30, no. 6, doi:doi:10.1002/jhet.5570300631, pages 1645 - 1651, XP002372543

DOI:   http://dx.doi.org/10.1002/jhet.5570300631
    - "Synthesis of Possible Metabolites of Medetomidine {1-(2,3-dimethylphenyl)-1-[imidazol-4(5)-yl]ethane", JOURNAL OF CHEMICAL RESEARCH, SYNOPSES, (1993), pages 152 - 3
    - SALONEN ET AL., "Biotransformation of Medetomidine in the Rat", XENOBIOTICA, (1990), vol. 20, no. 5, pages 471 - 80, XP009132244
    - "Pro-drugs as Novel Delivery System", T. HIGUCHI; V. STELLA, A.C.S. Symposium Series, vol. 14
    - PURE APPLI. CHEM., (1976), vol. 45, pages 11 - 13
    - Handbook of Pharmaceutical Salts, VERLAG HELVETICA CHEMICA ACTA-ZURICH, (2002), pages 329 - 345
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.